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Summary
Introduction. — Atherothrombosis is a systemic, diffuse disease associated with a high risk of
cardiovascular morbidity and mortality. It is the main cause of death in Western populations,
a major public health concern and its prevalence will further increase in the future.
Objectives. — To evaluate the rate of major vascular events at 1 year in French patients with
confirmed atherothrombotic disease, recruited in the REACH international registry.
Methods. — The REACH Registry has recruited 55.000 patients in 44 countries, aged at least 45 years
and suffering from established atherothrombotic disease (EAD). In France, 713 investigators
selected 3.514 patients with EAD between December 2003 and June 2004. Each investigator had to
include 5 to 10 patients presenting after a first documented event of cerebrovascular disease
(CVD), coronary artery disease (CAD) or lower limb peripheral arterial occlusive disease (PAD). The
patients were followed up for 1 year with collection of major vascular events.
Results. — Among the 3514 French patients with EAD in the REACH registry, 2.373 (68%) had
documented coronary disease, 778 (22%) had an ischemic stroke and 923 (26%) had documented
PAD. One quarter of CAD patients, one third of CVD patients and one half of PAD patients had
another atherothrombotic disease localization. Follow-up at 1 year was documented for 3.373
patients with EAD. The 1-year event rate in patients who had EAD was a function of the number
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of atherothrombotic localizations: the vascular death rate was 1.8% if there was a single
localization and 4.1% if there were 2 or 3 localizations, and the composite death, infarct and
stroke rates were 3.8% and 7.2% respectively and 11.7% and 22.3% respectively if hospitalizations
were added to the latter endpoint.
Conclusion. — The number of major vascular events during the first year is high in EAD patients
although these patients were followed up on an outpatient basis and are considered to be
stable. In patients with prior EAD, there was a close link between the incidence of major
vascular events and the number of symptomatic arterial beds (2 or 3 sites). The risk of a major
vascular event was twice as high in patients with polyvascular involvement than in those who
only had one affected artery.
© 2008 Published by Elsevier Masson SAS.
Résumé
Introduction. — L’athérothrombose, maladie globale et diffuse, est associée à un risque élevé
de morbi-mortalité cardio-vasculaires. Elle est la principale cause de décès dans la population
occidentale, véritable enjeu de santé publique et sa prévalence va augmenter dans les
prochaines années.
Objectifs. — Évaluer le taux d’événements vasculaires majeurs à 1 an chez les patients français
ayant une maladie athérothrombotique établie, inclus dans le registre international REACH.
Méthodes. — Le registre REACH a inclus 55 000 patients dans 44 pays, âgés d’au moins 45 ans et
souffrant d’une maladie athérothrombotique établie (MAE). En France, 713 médecins investigateurs
ont sélectionné 3 514 patients avec MAE entre décembre 2003 et juin 2004. Chaque investigateur
devait inclure 5 à 10 patients se présentant après un premier événement documenté de maladie
coronaire, cérébrovasculaire, ou souffrant d’une artériopathie oblitérante des membres inférieurs
(AOMI). Les patients ont été suivis pendant 1 an avec recueil des événements vasculaires majeurs.
Résultats. — Parmi les 3 514 patients français ayant une MAE du registre REACH, 2 373 (68 %)
avaient une maladie coronaire documentée, 778 (22 %) avaient une maladie ischémique
cérébrovasculaire et 923 (26 %) avaient une AOMI documentée. Un quart des coronariens, un
tiers des patients avec atteinte cérébrovasculaire et la moitié des artéritiques ont une autre
localisation athérothrombotique. Le suivi à 1 an a été documenté chez 3 373 patients ayant une
MAE. Le taux d’événements à 1 an chez les patients ayant une MAE est fonction du nombre de
localisations athérothrombotiques : le taux de décès vasculaire est de 1,8 % s’il existe une seule
localisation athérothrombotique et de 4,1 % s’il y a 2 ou 3 localisations athérothrombotiques,
le taux du critère combiné de décès, infarctus et AVC est de 3,8 % et de 7,2 % respectivement
et de 11,7 % et 22,3 % respectivement si les hospitalisations sont ajoutées au critère précédent.
Conclusion. — Le nombre d’événements vasculaires majeurs à 1 an est élevé chez les patients avec
MAE alors qu’il s’agit de patients suivis en ambulatoire et considérés comme stables. Chez les
patients ayant une MAE, il existe une relation étroite entre la fréquence de survenue des
événements vasculaires majeurs et le nombre de lits artériels symptomatiques (2 ou 3
localisations). Les patients ayant une atteinte polyvasculaire ont à ce titre un risque d’événements
vasculaires majeurs doublé par rapport à ceux qui n’ont qu’une seule atteinte artérielle.
© 2008 Published by Elsevier Masson SAS.
Introduction
It is common knowledge that atherothrombotic disease
remains a major public health problem. Cardiovascular
diseases cause every year the death of 16,500,000 people
worldwide including 4,400,000 from stroke. From an epide-
miological point of view, the INTERHEART study and the
WHO data are concordant and show that 9 major risk fac-
tors are responsible for more than 80% of cardiovascular
morbidity and mortality [1, 2]. 
Randomized studies have allowed a constant and rapid
improvement in the management of patients with a high
atherothrombotic risk. In this rapidly changing context, it
has became urgent to update data on therapeutic manage-
ment. Moreover, in order to better understand differences
in major cardiovascular event rates and patient outcomes
in different regions of the world, an international comparison
was essential, in order to determine, among other things, if
this international heterogeneity was due to different car-
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diovascular risk profiles between countries, or to differen-
ces in management practices and access to healthcare.
Until now, information available in registries about the
characteristics, management and prognosis of atherothrom-
botic patients or at high risk of atherothrombosis was limited
to a single geographical location (North America, Europe,
etc.), certain sub-groups of patients (post-infarction, stroke,
diabetics…), or inpatients and no outpatients in primary pre-
vention. The setting up of the REACH registry (REduction of
Atherothrombosis for Continued Health) worldwide, with
collection of data and a rigorous follow-up of patients,
answers this need for an updated global view of the manage-
ment and outcome of high-risk stable patients [3].
This article describes 1) the characteristics of the French
patients in the REACH registry with established atherothrom-
botic disease, 2) the therapeutic strategies implemented,
3) their prognosis, in particular as a function of the number
of localizations of atherothrombotic disease at baseline. 
Methods
The REACH Registry [3] recruited patients aged at least
45 years, signing an informed consent form, and who pre-
sented: 1) either a combination of at least three risk factors
and a high cardiovascular risk (man ≥ 65 years or woman
≥ 70 years, currently smoking >15 cigarettes/day with type
1 or II diabetes, hypercholesterolemia, diabetic nephropa-
thy, high blood pressure, ankle-brachial pressure index
(ABI) < 0.9, asymptomatic carotid stenosis ≥ 70%, or at least
one carotid plaque), 2) or stable established atherothrom-
botic disease (EAD) after a prior documented event: coro-
nary (stable angina, unstable angina, myocardial infarction,
angioplasty/stent, bypass), cerebrovascular (ischemic
stroke or transient ischemic attack), or lower limbs (peri-
pheral arterial occlusive disease), defined by current inter-
mittent claudication with an ankle-brachial index < 0.9 or a
history of surgery for intermittent claudication: angio-
plasty/stent, peripheral bypass or any other vascular proce-
dure including amputation) [3].
The goal of this registry was to conduct an objective
study of a contemporary population of stable patients in
different regions of the world in order to:
– describe the characteristics and management of these
patients globally and in each sub-group;
– evaluate atherothrombotic events in the total popula-
tion and each sub-group;
– estimate cross-risks among sub-groups;
– compare outcomes according to patient profiles;
– define predictors of subsequent atherothrombotic
events. 
Patients
Five to ten consecutive patients complying with the inclu-
sion criteria were recruited in each investigator center. The
investigators undertook to enroll all consecutive patients
complying with REACH registry selection criteria over the
predefined 7-month period. Treatment was left up to the
physicians’ choices during the whole of the follow-up
period.
To ensure uniform recruitment on a national scale, the
coordinators of each country, including France, validated
the choice of investigators to ensure that they were repre-
sentative of French healthcare practices in order to obtain
reliable epidemiological data. 
The data collected were the patients’ clinical characte-
ristics, risk factors, medical history, clinical examination
and laboratory test results. Data collection rules were iden-
tical in all the countries; once recorded locally, the data
were transferred to the Paris center for data processing and
statistical analysis. A rigorous audit was conducted on 10%
of the investigator centers in order to ensure the quality of
the data obtained.
The body mass index (BMI) was defined as weight in kilo-
grams divided by height (in meters) squared. Patients were
considered to be overweight if the BMI was between 25 and
29 kg/m2 and obese if the BMI was higher than 30 kg/m2,
and/or if their waist circumference exceeded 102 cm for
men or 88 cm for women [4]. Active smoking was defined by
a consumption of at least 5 cigarettes per day during the
month before recruitment, and past smoking by disconti-
nuation of tobacco intoxication for more than one month.
Polyvascular involvement was defined as documented
involvement of at least two arterial territories (CAD, CVD,
or lower limb PAD).
Subjects participating in a clinical trial or likely to have
difficulties in respecting the schedule of follow-up visits
were excluded.
Follow-up
At baseline, the following data were collected for all
patients by the investigator centers: major vascular events
(MVE), arterial revascularization procedures, weight and
body mass index, adherence to treatments. The same para-
meters were recorded for fol low-up at one year
(±3 months). Baseline characteristics were analyzed after
database lock in December 2005, and the follow-up results
at one year after database lock in June 2006. Initial follow-
up was planned at 12 months and 21 months and has
recently been extended to 3 and 4 years to obtain exhaus-
tive information.
Clinical events were reported by the investigator cen-
ters. Diagnosis of stroke or transient ischemic attack requi-
red diagnostic confirmation by a neurologist. Vascular
deaths comprised fatal stroke, fatal myocardial infarction
and other deaths of vascular origin. Other deaths of vascu-
lar origin comprised deaths due to pulmonary embolism,
sudden deaths, deaths after vascular surgery, percutaneous
revascularization or amputation, secondary to heart
failure, or visceral ischemia, and finally all deaths that
could not be assigned to a nonvascular cause or to hemor-
rhage. All deaths occurring during the 28 days after a myo-
cardial infarction or a stroke were considered to be fatal
myocardial infarctions or strokes.
Statistics
Continuous variables are expressed in the form of means
(with standard deviations), and categorical variables are
presented as incidences and percentages. Clinical events
are reported in annual event rates, after adjustment for
age and sex. Only patients with complete data were inclu-
ded in the calculation of the cumulative event rate. Statis-
tical differences between the incidence of events according
to the type or number of atherothrombotic sites were
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tested using the trend test of the Cox proportional hazard
model. Statistical analyzes were conducted using SAS v8
software (SAS Institute Inc, Cary, NC).
Results
Data at baseline
The REACH registry recruited a total of 67.888 patients in
5.473 centers in 44 countries on all five continents between
December 2003 and June 2004. In France, 713 investigators
[543 general practitioners (76.2%), 64 cardiologists (9%),
36 angiologists (5.1%), 23 internists (3.2%), 13 endocrinolo-
gists (3.2%), 17 neurologists (2.4%) and 7 other physicians]
recruited 4.740 patients. 4.693 of these subjects were
enrolled [i.e. 46 ineligible patients (1%) and one withdrawal
of consent], including 3.514 patients presenting established
atherothrombotic disease (EAD), and 1226 patients with at
least three CV risk factors (who are not analyzed here). The
analysis presented in this article only concerns the 3.514
patients with prior EAD. 
At baseline, the sample of subjects presented the fol-
lowing clinical characteristics (table 1): average age
69.3 years, 76.5% men, 30.8% diabetics, 71.5% with hyper-
tension, 74.2% with hypercholesterolemia, 14.3% smokers,
49.7% past smokers. 47.3% and 22.6% of patients were over-
weight and obese respectively.
From the vascular point of view, 81.8% of patients had a
single arterial localization: CAD in 53.4% of cases, CVD in
14.9%, and PAD in 13.4% of patients (figure 1). In addition,
18.2% of patients had polyvascular disease including more
than half (9.8%) with simultaneous involvement of the coro-
nary arteries and the lower limbs. More than seventy per-
cent of polyvascular patients were affected by lower limb
PAD. One quarter of the CAD patients, one third of CVD
patients, and more than half of PAD patients had another
affected arterial site.
The main cardiovascular medications used are presented
in table 2. During the visit, 91.3% of patients with documen-
ted hypertension or with high blood pressure, received at
least one antihypertensive drug. Likewise, 29.1% of the
total EAD patients included 30.8% of diabetics or patients
with elevated blood glucose levels, received antidiabetic
medication. Treatments with statins and antiplatelet
agents, indicated in all patients, were prescribed in 70.1%
and 82.6% of subjects, respectively. Although theses medi-
cations were widely prescribed, treatment goals were
Table 1 Demographic characteristics of patients recrui-
ted in France in the REACH registry.
  Established  atherothrombotic  
disease
N = 3.514
Average age (years) (EC) 
Male gender (%)
Diabetes (%)
Hypertension (%)
Hypercholesterolemia (%)
Excess bodyweight BMI: 
[25-30] (%)
Obesity BMI > 30 (%)
Past smoking (%)
Current smoking (%)
69.3 (10.3)
76.5
30.8
71.5
74.2
47.3
22.6
49.7
14.3
5.4
18.2
13.4
14.9
9.8
1.8
1.3
53.4
81.8
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Figure 1. Prevalence of polyvascular involvement in patients with documented atherothrombotic disease recruited in France in the
REACH registry (n=3.514).
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rarely achieved as 73% of the patients had a blood pressure
equal to or higher than 140/90 mmHg, 53% had a total cho-
lesterol above 2 grams per liter, and 19% of patients smo-
ked > 5 cigarettes per day.
Patient data at one year
In France, 96.2% (n=4514) of the patients recruited were
followed up at one year. In all, 226 patients (4.8%) were
lost to follow-up: 138 patients (2.9%) did not come to the
follow-up visit, and 41 patients (0.9%) were excluded
because of the withdrawal of the center.
The cumulative major vascular event rates at one year
for patients with EAD (table 3) were 2.3% for vascular
deaths, 4.5% for the primary composite endpoint (vascular
deaths, nonfatal MI, nonfatal stroke), and 13.7% for the
secondary composite endpoint (vascular deaths, nonfatal
MI, nonfatal stroke, hospitalization for an atherothrombotic
event).
The primary endpoint was 4.7% in CAD patients, 3.8% in
PAD patients and increased to 5.8% in CVD patients respec-
tively because of the high incidence of recurrences of non-
fatal stroke in this population (3.4% of recurrences). If
hospitalizations were added to this composite endpoint,
the event rate concerned nearly one patient out of 7 for the
population presenting an EAD, and up to 1 out of 5 for
patients with peripheral arterial occlusive disease. All
comparisons were statistically significant.
These rates increased with the number of localizations of
atherothrombotic disease (table 4). For cardiovascular
deaths, the annual incidence ranged between 1.8% in sub-
jects with an isolated vascular lesion and 4.1% for subjects
with 2 vascular lesions or more. For the primary composite
endpoint, these figures were 3.8% and 7.2% respectively
(p<0.001). For the secondary composite endpoint, these
annual rates were 11.7% and 22.3% respectively (p<0.001).
The main reasons for hospitalization during follow-up
were the occurrence of unstable angina (4%), transient
ischemic attack (0.9%), another ischemic arterial event
(2.8%), or chronic heart failure (3.6%) (table 3). The occur-
rence of a hemorrhage (requiring hospitalization or trans-
fusion) was only reported in 0.6% of patients.
Tableau 2 Treatments at baseline of patients recruited in France 
in the REACH registry.
Established  
atherothrombotic
disease 
N=3.514
No. of patients with diagnosed hypertension or elevated 
blood pressure at initial examination (n)
 – At least one antihypertensive treatment (%)
 – Beta-blockers (%)
 – ACE inhibitors (%)
 – Angiotensin II receptor blockers(%) 
 – Diuretics (%)
 – Calcium channel blockers (%) 
 – Other antihypertensive agents (%)
• Antiplatelet therapy *
– At least one antiplatelet agent (%)
– Aspirin (%)
– Other antiplatelet agent (%)
– 2 antiplatelet agents (%)
• Lipid-lowering therapy *
 – At least 1 lipid-lowering agent (%)
 – Statins (%)
 – Other lipid-lowering agents (%)
No. of patients with history of diabetes or elevated 
blood glucose at initial examination (n)
 – At least 1 diabetes medication (%)*
 – Sulphonilurea (%)*
 – Biguanides (%)*
 – Insulin (%) *
 – Thiazolidinediones (%)*
 – Other antidiabetic treatments (%)*
• Nitrates (%)*
2512
91.3
49.3
40.1
19.6
39.9
36.1
8.0
82.6
59.4
34.8
11.4
78.7
70.1
9.9
1083
29.1
11.8
14.2
9.2
1.3
5.5
29.4
*Percents base on total EAD population.
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Discussion
The REACH registry is the first worldwide epidemiological
study on a population of atherothrombotic patients [3]. The
French patients in this registry represent a large cohort per-
mitting valid statistical analysis. Several fundamental points
may be made after examining the French registry data.
Patients’ characteristics
French patients with established atherothrombotic disease
(EAD) have a classic risk profile. Comparative analysis with
previous French epidemiological data, in the pooled analy-
sis of the ECLAT, APRES and PRISMA studies, conducted in
1999-2000 by V. Bongard et al. [5] in 14,544 patients with a
Table 3 Major vascular event rates at 1 year in the total population and within sub-groups with documented athe-
rothrombotic disease, according to territory (data adjusted for age, sex, smoking, high blood pressure, diabetes and
hypercholesterolemia).
Event
Established 
atherothrombotic 
disease
CAD CVD PAD
All-cause mortality %
(95% CI)
Major vascular events
Vascular death (%)
(95% CI)
Non-fatal MI (%)
(95% CI)
Non-fatal stroke (%)
(95% CI)
Vascular death/MI/stroke (%)
(95% CI)
Vascular death /MI/stroke or hospitalization due 
to atherothrombotic events (%)
(95% CI)
Other vascular events leading to hospitalization
Unstable angina (%)
(95% CI)
Transient Ischemic Attack (%)
(95% CI)
Other arterial ischemic events (%)
(95% CI)
Chronic heart failure;
(95% CI)
Hemorrhage
(95% CI)
New diagnosis/worsening of intermittent claudication (%)
(95% CI)
n = 3.373
3.5
(1.7 ; 5.2)
2.3
0.8 ; 3.8)
1.0
(0.1 ; 1.9)
1.5
(0.4 ; 2.6)
4.5
(2.5 ; 6.4)
13.7
10.8 ; 16.5)
4.0
(2.2 ; 5.7)
0.9
(0.1 ; 1.8)
2.8
(1.3 ; 4.3)
3.6
(1.9 ; 5.2)
0.6
(0.1 ; 1.2)
2.7
(1.2 ; 4.1)
n = 2.373
4.1
(1.9 ; 6.1)
2.8
0.9 ; 4.5)
1.2
1.4
(0.3 ; 2.4)
4.9
(2.7 ; 7.0)
14.1
(11.0 ; 17.0)
5.4
(3.0 ; 7.7)
0.5
(0.0 ; 1.1)
2.4
(1.0 ; 3.7)
4.3
(2.3 ; 6.3)
0.5
(0.0 ; 1.1)
2.5
(1.0 ; 3.9)
n = 778
2.9
(1.0 ; 4.7)
1.7
(0.3 ; 3.1)
0.8
3.4
(0.7 ; 6.1)
5.8
(2.8 ; 8.6)
13.1
(9.6 ; 16.4)
1.6
(0.5 ; 2.8)
2.8
(0.3 ; 5.4)
1.9
(0.5 ; 3.3)
3.1
(1.3 ; 4.8)
0.4
(0.0 ; 1.1)
1.9
(0.5 ; 3.3)
n = 879
4.0
(1.6 ; 6.4)
2.9
(0.7 ; 5.1)
0.8
0.6
(0.0 ; 1.3)
3.8
(1.7 ; 5.9)
18.6
(14.4 ; 22.6)
3 .0
(1.3 ; 4.7)
1.0
(0.0 ; 2.0)
7.2
(3.3 ; 10.8)
4.0
(1.8 ; 6.0)
0.9
(0.0 ; 1.9)
7.3
(3.3 ; 11.1)
Tableau 4 Major vascular event rates at 1 year, according to the number of atherothrombotic localizations (data
adjusted for age, sex, smoking, high blood pressure, diabetes and hypercholesterolemia).
Event 1 localization 2 or 3 localizations p
Vascular death (%) (95% CI)
Non fatal MI (%) (95% CI)
Non fatal stroke (%) (95% CI)
Vascular death/MI/stroke (%) (95% CI)
Vascular death /MI/stroke or hospitalization 
due to atherothrombotic events (95% CI)
n = 2.772
1.8 (0.6 ; 3.0)
1.0 (0.1 ; 1.8)
1.2 (0.3 ; 2.1)
3.8 (2.1 ; 5.5)
11.7 (9.1 ; 14.3)
n = 601
4.1 (0.9 ; 7.1)
1.1 (0.0 ; 2.4)
2.8 (0.4 ; 5.2)
7.2 (3.4 ; 10.8)
22.3 (17.3 ; 27.1)
< 0.001
 0.01
< 0.001
< 0.001
< 0.001
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history of an atherothrombotic event, showed that the pro-
file of risk factors has changed in a few years: The percen-
tages of diabetics, hypercholesterolemic subjects, obese or
smokers (active or previous) has increased. One of the
explanations of this increase in the number of patients with
risk factors could be improved screening and/or changes in
diagnostic cut-offs in particular for hypercholesterolemia,
high blood pressure or diabetes. 
The profiles of French patients in the REACH registry [6]
are similar to those of patients recruited in Europe (West or
East), but also on other continents (North America, Latin
America, Asia, Middle East), with a few slight differences,
expect for diabetes witch is more marked in North America
and Asia. These data confirm the results of recent epide-
miological studies [1, 2] which underline the predominant
role of major risk factors (smoking, hypertension, dyslipide-
mia, type 2 diabetes, abdominal obesity) in the genesis of
major vascular events, and confirm the universal nature of
the risk factors.
Cardiovascular morbidity and mortality in EAD
The number of vascular events is high in EAD patients
although these patients were followed up on an outpatient
basis and are considered to be stable. The 1-year major
vascular event rate for French patients was high, since it
was 3.5% for all-cause mortality, and higher in CAD or PAD
patients (4.1% and 4% respectively) compared to CVD
patients (2.9%). Usually the all-cause mortality rate is
higher in PAD patients than the over EAD population; the
small number of patient in the REACH France PAD group
could explain this unexpected finding. In the worldwide
registry data we observe the usual increase of all-cause
mortality between CAD, CVD and PAD patients [6]. The
major vascular event rate for the composite endpoint
(vascular deaths, MI and stroke) was also high at one year.
If hospitalizations were added to this composite endpoint,
the event rate concerned nearly one patient out of 7 for
the population presenting an EAD, and up to 1 out of 5 for
patients with peripheral arterial occlusive disease. For
polyvascular patients near one patient out of 4 present a
vascular event or hospitalization for ischemic reason at
one year follow-up. This data is all the more worrying as
earlier French epidemiological data from the APRES study
[7], in a similar population of patients with a history of at
least one atherothrombotic event (documented MI, non-
embolic ischemic stroke or peripheral arterial occlusive
disease), seen by general practitioners between 1999 and
2000, gave a 1-year event rate (MI, ischemic stroke and
cardiovascular death) of 3.8%, with a cardiovascular death
rate of 1.3% (versus 4. 5% and 2.3% in the REACH registry
France).
A geographical analysis shows that the major vascular
event rate for the composite endpoint in France was similar
to that observed in Western Europe, North America, and
Australia. It was lower than event rates noted in Eastern
Europe and Latin America, and higher than that observed in
Japan. These differences may be explained by geographical
differences in lifestyle, but also by differences in health-
care systems and health policies. An improvement in thera-
peutic management of patients in France also seems to be
necessary, since 73% of hypertensive patients did not
achieve target blood pressure values, 50% of dyslipidemic
patients still had total cholesterol levels higher than 2 g/l,
and 14.3% of patients continued to smoke. The causes of
the unsatisfactory control of risk factors are undoubtedly
multifactorial and inherent to some extent to the patients
themselves (adherence, concomitant diseases, resistance
factors to treatment), but are also probably related to a
certain “therapeutic inertia” noted during other French
epidemiologic studies [8, 9] and also internationally, since
in our French registry, antiplatelet agents and statins were
not prescribed in 17 and 30% of patients respectively, whe-
reas insulin treatment was only used in 9.2% of diabetics
with EAD . 
Polyvascular involvement consequences
Polyvascular involvement was frequent, since it concerned
a quarter of CAD patients, one third of CVD patients, and
half the PAD patients. More than seventy percent of poly-
vascular patients are PAD patients. This polyvascular invol-
vement conditioned patient outcomes. The event rate
increased linearly according to the number of atherothrom-
botic sites. It could reinforce the importance of polyvascu-
lar diagnosis by the detection of PAD patients.
This French data on the prognostic role of polyvascular
involvement is confirmed by the worldwide results of the
REACH registry, which showed that in patients with an EAD,
there was a quasi-linear relation between the incidence of
vascular events and the number of symptomatic arterial
beds [3,4,6]. 
Whereas patients in secondary prevention have traditio-
nally been considered globally, with no stratification of
risk, this new data provides invaluable information and a
real change of paradigm, by showing the heterogeneity of
risk level in patients with EAD, directly correlated with the
number of symptomatic vascular beds.
These innovative data should help us refine therapeu-
tic strategies and objectives in order to intensify the
management of certain groups of patients at increased
risk.
Type of vascular event and EAD topography
Another important finding of the REACH registry is that for
these EAD patients, recurrences during the first year gene-
rally occurred in the initially affected arterial bed (acute
coronary syndromes after myocardial infarction, recurrence
of stroke during secondary prevention of ischemic stroke).
The short time between the initial event and the recur-
rence of the ischemic event probably explains why these
events have the same localization, though recurrences of
stroke were nevertheless more frequent than recurrences
of MI in the population of patients with EAD. In the Oxford
Vascular Study [10] which was a population-based survey,
the incidence of stroke was at least as high or even higher
than the incidence of MI. The relative incidence of stroke
compared to MI was 1.1 to 1.2. corresponding to 10 to 20%
more events.
PAD patients have a high risk of vascular death. Two
complementary physiopathological mechanisms may explain
this result: PAD patients are very often polyvascular
patients; paradoxically these patients often benefit from
fewer validated treatments and/or less frequently achieve
blood pressure, lipid or glucose goals. In these PAD
patients, 7.3% presented a worsening of their claudication
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requiring hospitalization, contrasting with previously docu-
mented epidemiological data on arteritis patients.
The global risk of hemorrhage requiring hospitalization or
transfusion was low (0.6%), with a benefit-risk ratio which
seems all the more positive as the absolute vascular risk of
these patients was high.
Study limitation
Despite the quality data collection, the REACH registry is
not a prevalence study and theses results cannot be extra-
polated to the whole population of French atherothrombo-
tic patients. The desire of certain physicians to take part in
the study may have lead to the selection of patients recei-
ving the best treatment and follow-up, though this would
have led to an underestimation of risk, which is already
high in our registry. On the other hand, it is a partial geo-
graphic analysis of a global registry witch can explain some
statistical issue. No sample size calculation was perform for
the french population. Finally, no conclusion may be about
why the recommended treatments for patients with EAD
were underutilized. This may have been due to therapeutic
inertia and/or the presence of co-morbidities or concomi-
tant diseases contra-indicating the use of these therapies.
Conclusion
The French REACH registry data showed that there is a high
one-year major vascular event rate in stable outpatients
with established atherothrombotic disease. This event rate
is similar to the rates observed in other areas of the world,
in particular in Western Europe and North America. Poly-
vascular involvement is frequent and constitutes a potent
risk marker of vascular morbidity and mortality, since it
doubles the risk of major vascular events compared to
involvement of a single arterial bed. The number of arterial
beds is therefore a better predictor of outcome than the
type of arterial bed initially affected. Patients with esta-
blished atherothrombotic disease have a heterogeneous
level of risk requiring optimization of their management
with an essential stepping up of validated treatments. This
must go hand in hand with optimization of the control of
the main cardiovascular risk factors. The use of antiplatelet
agents is all the more effective when the vascular risk is
high. All these epidemiological data confirm the validity of
the global approach to atherothrombosis, and not its seg-
mentation according to the initially affected arterial bed. 
References
[1] Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modi-
fiable risk factors associated with myocardial infarction in 52
countries (the INTERHEART study): case-control study. Lancet
2004;364:937-52.
[2] The World Health Report. Reducing risks, promoting healthy
lives. World Health Organization. Geneva (Switzerland);
2002.
[3] Ohman EM, Bhatt DL, Steg PG, et al. The Reduction of Athe-
rothrombosis for Continued Health (REACH) Registry: an inter-
national, prospective, observational investigation in subjects
at risk for atherothrombotic events-study design. Am Heart J
2006;151:e1-e10.
[4] Bhatt DL, Steg PG, Ohman EM, et al. International Prevalence,
Recognition, and Treatment of Cardiovascular Risk Factors in
Outpatients With Atherothrombosis. JAMA 2006;295:180-9. 
[5] Bongard V, Cambou JP, Leizorovicz A et al. Comparaison of
cardiovascular factors and drug use in 14 544 french Patients
with a history of myocardial infarction, ischemic stroke and /
or peripheral arterial disease. Eur J Cardiovasc Prev Rehabil
2004;11:394-402.
[6] Steg PG, Bhatt DL, Wilson PWF, et al. One-Year Cardiovascular
Event Rates in Outpatients With Atherothrombosis. JAMA
2007;297:1197-206.
[7] Ferrières J, Cambou JP, Gayet JL et al. Prognosis of patients
with atherothrombotic disease: a prospective survey in a non-
hospital setting. Int J Cardiol 2006;112:302-7. 
[8] Sabouret P, Denolle T, Krempf M, Om S, Laville M. Enquête
MICROALB :Dépistage de la microalbuminurie chez l’hypertendu
diabétique de type 2 par le médecin généraliste en France
métropolitaine. Arch Mal Cœur et Vaisseaux 2006;99:712-7.
[9] Van Ganse E, Souchet T, Laforest L, et al Long-term achieve-
ment of the therapeutic objectives of lipid-lowering agents in
primary prevention patiens and cardiovascular outcomes:an
observational study. Atherosclerosis 2006;185:58-64.
[10] Rothwell PM, Coull AJ, Silver LE, et al. Population-based study
of event-rate, incidence, case fatality, and mortality for all
acute vascular events in all arterial territories (Oxford Vascu-
lar Study). Lancet 2005;366:1773-83. 
